Soligenix Reports 75% Response Rate for HyBryte™ in Rare Skin Cancer Trial
April 25th, 2025 1:05 PM
By: Advos Staff Reporter
Soligenix's HyBryte™ demonstrates promising results in a clinical trial for cutaneous T-cell lymphoma, achieving a 75% response rate with a novel light-activated therapy. The breakthrough could offer new treatment options for patients with this rare form of skin cancer.
Soligenix, a late-stage biopharmaceutical company, has reported significant progress in developing HyBryte™, a first-in-class photodynamic therapy for treating cutaneous T-cell lymphoma (CTCL), a rare form of skin cancer. The clinical trial, supported by a U.S. Food and Drug Administration Orphan Products Development Grant, revealed a 75% response rate using a non-invasive, light-activated treatment approach.
The innovative therapy utilizes safe visible light to target cancer cells, distinguishing itself from traditional treatment methods. HyBryte™ has already received Orphan Drug and Fast Track designations, signaling potential regulatory advantages and recognition of its unique therapeutic approach.
This development is crucial for patients with CTCL, a disease with limited treatment options. The high response rate suggests HyBryte™ could provide a meaningful alternative for individuals struggling with this rare skin cancer, potentially improving treatment outcomes and patient quality of life.
Soligenix is positioning the therapy for potential commercialization, with plans to continue advancing regulatory discussions. The successful completion of the second Phase 3 study marks a significant milestone in the company's efforts to address unmet medical needs in rare disease treatment.
Source Statement
This news article relied primarily on a press release disributed by InvestorBrandNetwork (IBN). You can read the source press release here,
